CRSP vs NTLA
CRSP and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $5.01B | $1.59B |
| P/S | 1427.0x | 23.6x |
| Revenue growth (YoY) | -90.6% | 16.9% |
| Earnings growth (YoY) | -58.8% | 20.5% |
| EBIT margin | -18933.6% | -651.7% |
| ROE | -33.3% | -56.7% |
| ROIC | -32.6% | — |
| 1y total return | -10.5% | -1.6% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: CRSP frente a NTLA
| Métrica | CRSP | NTLA |
|---|---|---|
| Valor final | $36.8K | $9.0K |
| Retorno total | +267.9% | -9.9% |
| CAGR | +14.1% | -1.1% |
| Volatilidad | 64.0% | 78.6% |
| Sharpe | 0.46 | 0.33 |
| Sortino | 0.71 | 0.48 |
| Caída máxima | -85.1% | -96.5% |
Basado en 2489 días de negociación comunes, 2016-10-19 → 2026-09-15 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)